HGH Fragment 176-191

aka HGH Frag 176-191 · Fragment 176-191 · hGH 176-191 · Growth Hormone Fragment 176-191

GLP-1 / Metabolic research-only

Mechanism

Synthetic 16-amino-acid peptide corresponding to the C-terminal region (residues 176-191) of human growth hormone, stabilized by a disulfide bridge between its two cysteine residues. It was developed at Monash University (Australia) to isolate growth hormone's lipolytic activity: it is reported to stimulate fat breakdown and inhibit lipogenesis while lacking the growth-promoting and insulin-antagonizing effects of full-length GH, since it does not meaningfully activate the GH receptor or raise IGF-1. It is not FDA-approved for any human indication and exists as a research/grey-market compound; the related Tyr-modified analog AOD-9604 failed to meet primary endpoints in an obesity clinical trial.

Studied uses

fat-loss and body-composition research (research only)
lipolysis and metabolic studies in animal models
investigational adjunct in obesity research (unapproved)

Identification

Molecular formula	C80H127N23O24S2
Sequence	`YLRIVQCRSVEGSCGF`
Typical dose	250-500 mcg/day subcutaneous (vendor/anecdotal norms; no established clinical dosing)
Half-life	Short; reported on the order of minutes in plasma (limited human pharmacokinetic data)

Safety

Not FDA-approved for human therapeutic use; sold as a research chemical in most jurisdictions. Human efficacy and long-term safety data are limited. WADA does not list this specific fragment by name, but growth-hormone fragments and GH-modulating agents fall in a scrutinized class for athletes.

Vendors selling HGH Fragment 176-191

Vendor	Size	Price	Listed purity	Trust
DongCheng Peptide	—	—	—	46
zztai Peptide Ltd	—	—	—	43

Research

Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells

Habibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA. · Drug design, development and therapy (2022) ·

Introduction Numerous drugs with potent toxicity against cancer cells are available for treating malignancies, but therapeutic efficacies are limited due to their inefficient tumor targeting and deleterious effects on non-cancerous tissue.

source →